Anticoagulant and Antiplatelet Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease

<table>GI: gastrointestinal, ICH: intracerebral hemorrhage. Efficacy and safety outcomes in RELY, ARISTOTLE and ROCKET-AF [<a href="/journals/thrombosis/2012/184573/#B23">22</a>, <a href="/journals/thrombosis/2012/184573/#B24">23</a>, <a href="/journals/thrombosis/2012/184573/#B26">25</a>]. Results are displayed for Dabigatran 150 mg bid.</table>

Thrombosis

fig1

Figure 1

Figure 1: Anticoagulant and Antiplatelet Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease 